CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr | ₹4,591 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹5,484 Cr |
| Mar2024 | ₹5,246 Cr |
| Mar2023 | ₹5,033 Cr |
| Mar2022 | ₹4,913 Cr |
| Mar2021 | ₹4,591 Cr |
How is Total Current Liabilities of CIPLA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,484 Cr | 4.54 | |
| Mar2024 | ₹5,246 Cr | 4.22 | |
| Mar2023 | ₹5,033 Cr | 2.45 | |
| Mar2022 | ₹4,913 Cr | 7.01 | |
| Mar2021 | ₹4,591 Cr | - | |
Compare Total Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹118,427.5 Cr | -4.2% | -3.1% | -1.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹416,728.0 Cr | -1.3% | -3.9% | -5.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,248.0 Cr | -2.3% | 0.9% | 12.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹133,627.0 Cr | 0.3% | 3.9% | 19.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,462.0 Cr | -3.2% | -4.5% | -11.8% | Stock Analytics | |
| MANKIND PHARMA | ₹91,927.6 Cr | -0.7% | 2.8% | -23.5% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -4.2% |
-3.1% |
-1.9% |
| SENSEX | -1.8% |
-0.6% |
7.3% |
You may also like the below Video Courses